Table 1.
Baseline and treatment characteristics of the entire cohort and by time period
| Characteristic | Entire cohort (N = 1551) | 2010-2014 (N = 525) | 2005-2009 (N = 604) | 2000-2004 (n = 422) | P, entire cohort | P, 2005-2009 vs 2010-2014 |
|---|---|---|---|---|---|---|
| Age, y, median (IQR) | 63 (55-70) | 63 (56-71) | 62 (55-69) | 62 (54-69) | .08 | .03 |
| Age ≥65 y, n (%) | 688 (44) | 253 (48) | 248 (41) | 187 (44) | .055 | .01 |
| Male, n (%) | 976 (63) | 337 (64) | 376 (62) | 263 (62) | .76 | .5 |
| Organ involved, n (%) | ||||||
| >2 organs | 307 (20) | 79 (15) | 145 (24) | 83 (20) | <.001 | <.001 |
| Cardiac | 1173 (76) | 375 (71) | 478 (79) | 320 (76) | .01 | .002 |
| Renal | 947 (61) | 307 (58) | 396 (66) | 244 (58) | .01 | .01 |
| Hepatic | 329 (21) | 84 (16) | 131 (22) | 114 (27) | <.001 | .01 |
| Neurological | 318 (21) | 120 (23) | 127 (21) | 71 (17%) | .06 | .45 |
| λ restricted, n (%) | 1166 (75) | 397 (76) | 460 (76) | 309 (73) | .54 | .83 |
| BMPCs, median (IQR) | 10 (7-20) | 10 (6-20) | 10 (6-20) | 12 (8-22) | .06 | .76 |
| dFLC | n = 1356 | n = 523 | n = 594 | n = 239 | ||
| Median, mg/dL (IQR) | 23.7 (10.4-62.2) | 24.5 (10.1-62.1) | 22.3 (9.5-61.6) | 24.8 (12.8-64.5) | .17 | .33 |
| ≥18 mg/dL, n (%) | 803 (59) | 305 (58) | 344 (58) | 154 (64) | .18 | .89 |
| NT-proBNP | n = 1132 | n = 501 | n = 556 | n = 75 | ||
| Median, pg/mL (IQR) | 2438 (470-7025) | 2389 (424-6669) | 2475 (561-7310) | 1767 (406-8286) | .4 | .2 |
| ≥8500 pg/mL, n (%) | 224 (21) | 102 (20) | 122 (22) | 17 (23) | .78 | .52 |
| Troponin T | n = 1321 | n = 509 | n = 584 | n = 228 | ||
| Median, ng/mL (IQR) | 0.03 (<0.01-0.08) | 0.02 (<0.01-0.07) | 0.03 (<0.01-0.09) | 0.03 (<0.01-0.09) | .008 | .003 |
| ≥0.035 ng/mL, n (%) | 610 (46) | 216 (42) | 281 (48) | 113 (5) | .09 | .06 |
| ≥0.06 ng/mL, n (%) | 463 (35) | 151 (30) | 224 (38) | 88 (39) | .004 | .002 |
| eGFR, mL/min per 1.73 m2, median (IQR) | 64 (45-79) | 66 (47-86) | 64 (43-79) | 59 (43-71) | <.001 | .010 |
| eGFR <30 mL/min per 1.73 m2, n (%) | 198 (13) | 52 (10) | 87 (14) | 59 (14) | .05 | .02 |
| Urinary proteinuria, g per 24 h, median (IQR) | 1.4 (0.2-5.7) | 1.2 (0.2-5.3) | 1.6 (0.2-5.9) | 1.4 (0.2-5.8) | .39 | .18 |
| Mayo AL amyloidosis 2004 stage, % | n = 1123 | n = 498 | n = 552 | n = 73 | ||
| I/II/III | 19/38/43 | 21/38/41 | 16/39/45 | 23/30/47 | .16 | .11 |
| Mayo AL amyloidosis 2012 stage, % | n = 1206 | n = 503 | n = 572 | n = 131 | ||
| I/II/III/IV | 21/22/25/32 | 23/23/23/31 | 19/22/27/32 | 24/24/20/32 | .64 | .43 |
| Treatment categories, n (%)* | <.001 | <.001 | ||||
| ASCT | 482 (31) | 172 (33) | 177 (29) | 133 (32) | ||
| MP | 155 (10) | 2 (<1) | 12 (2) | 141 (34) | ||
| MDex | 420 (27) | 97 (18) | 288 (48) | 35 (8) | ||
| Bortezomib-based | 222 (14) | 201 (38) | 20 (3) | 1 (<1) | ||
| IMiD-based | 58 (4) | 10 (2) | 30 (5) | 18 (4) | ||
| Single-agent dexamethasone | 42 (3) | 0 | 16 (3) | 26 (6) | ||
| Unknown | 46 (3) | 10 (2) | 20 (3) | 16 (4) | ||
| No treatment | 120 (8) | 33 (6) | 40 (7) | 47 (11) | ||
| Hematological response to first-line treatment (n = 966) (%) | <.001 | .008 | ||||
| CR | 335 (35) | 137 (36) | 145 (36) | 53 (29) | ||
| VGPR | 241 (25) | 113 (30) | 88 (22) | 40 (22) | ||
| PR | 208 (21) | 81 (21.5) | 92 (22) | 35 (19) | ||
| NR | 182 (19) | 47 (12.5) | 80 (20) | 55 (30) |
Boldface indicates significance at P < .05.
CR, complete response; NR, no response.
*
6 patients received other forms of therapy.